
Reta-Peptide
Tirzepatide
Finnrick tested 8 samples of Tirzepatide (GLP-1 and GIP antagonist) from Reta-Peptide between 20 Jun 2025 and 18 Sep 2025. Test scores average over 7, no score below 6, and at least 6 tests warrant a confident Finnrick Rating of A (Great).
Finnrick Rating™
Reta-Peptide
Tirzepatide
Tested 8 Samples
Last test 18 Sep 2025
Take Action
Researcher
Request Full Data Access to the Finnrick database of peptide tests.
Free peptide testing
Mail in a sample (US only) to get confidence for the specific vials you have, and contribute to identifying unsafe supply chains, so other people can avoid risky and costly mistakes.
Other Tirzepatide tests from top-rated vendors:
All Tirzepatide tests from Reta-Peptide
Samples are tested in commercial labs
Tests Count
8
Scores
AVGMINMAX
Last
18 Sep 2025
First
20 Jun 2025
Quantity | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Test Date | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
18 Sep 2025 | View | 30mg | 31.800mg | +6.0% | 99.95% | (no batch ID) | No Label / Silver Crimp / Green Cap | Lab E | Public | |
4 Sep 2025 | View | 15mg | 14.800mg | -1.3% | 99.95% | (no batch ID) | Clear Label / Silver Crimp / Clear Pink Cap | Lab E | Public | |
4 Sep 2025 | View | 30mg | 29.800mg | -0.7% | 99.95% | 7.30.25 | White Label / Silver Crimp / Clear Cap | Lab E | Public | |
4 Sep 2025 | View | 5mg | 5.150mg | +3.0% | 99.62% | July 17, 2025 | No Label / Silver Crimp / White Cap | Lab E | Public | |
21 Aug 2025 | View | 30mg | 31.900mg | +6.3% | 99.75% | (no batch ID) | No Label / Silver Crimp / Violet Cap | Lab E | Public | |
25 Jul 2025 | View | 20mg | 19.500mg | -2.5% | 99.95% | (no batch ID) | White Label / Silver Crimp / Violet Cap | Lab E | Public | |
16 Jul 2025 | View | 30mg | 30.300mg | +1.0% | 99.87% | (no batch ID) | No Label / Silver Crimp / Pink Cap | Lab E | Public | |
20 Jun 2025 | View | 20mg | 18.700mg | -6.5% | 99.83% | (no batch ID) | White Label / Silver Crimp / Purple Cap | Lab E | Public |